Endometrial Genomic Profile in Endometrial Priming

Instituto Valenciano de Infertilidad, IVI VALENCIA6 enrolled

Overview

The aim of this study is to analyse genomics profile expression in endometrium under different endometrial priming for recipients.

We analyze the genomic profile of egg donors in different endometrial priming protocols, compared with natural cycle, including the conventional single long acting GnRH agonist injection in the mid luteal phase of the previous cycle of the endometrial priming and the single daily antagonist injection (Cetrorelix 0.25 mg) administered in the early follicular phase followed by endometrial priming. Endometrial biopsy will be taken in luteinizing hormone * 7 or with P4 +5 in cases with endometrial priming with oestrogens therapy.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Genomic Human Endometrial Expression Profile

Interventions

endometrial biopsyPROCEDURE

endometrial biopsy

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 35 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * 6 egg healthy volunteer egg donors. * Volunteers. * 18-35 years old * Healthy. * BMI \<28. Exclusion Criteria: * \- BMI \> 28 * Smokers-

Locations (1)

Ivi Valencia

Valencia, Valencia, Spain

Outcomes

Primary Outcomes

genetic endometrial human profile expression

implantation related genes profile expression

Time frame: Oocyte donors will be followed up for four to six months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.